Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial

Association of Cytomegalovirus Infection and Disease With Death and Graft Loss After Liver Transplant in High-Risk Recipients

(2011) W. Bosch et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

(2011) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

(2010) R.K. Avery et al.   Transplant Infectious Disease

International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

(2010) Camille N. Kotton et al.   TRANSPLANTATION

Cytomegalovirus in Solid Organ Transplant Recipients

(2009) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

(2008) D. J. Winston et al.   BLOOD

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir

(2008) Sunwen Chou   REVIEWS IN MEDICAL VIROLOGY

Cytomegalovirus infection after liver transplantation: Current concepts and challenges

(2008) Raymund-Rabe Razonable   WORLD JOURNAL OF GASTROENTEROLOGY